Intrinsic Subtypes and Gene Expression Profiles in Primary and Metastatic Breast Cancer


Por: Cejalvo J, De Duenas E, Galvan P, Garcia-Recio S, Gasion O, Pare L, Antolin S, Martinello R, Blancas I, Adamo B, Guerrero-Zotano A, Munoz M, Nuciforow P, Vidal M, Perez R, Lopez-Muniz J, Caballero R, Peg V, Carrasco E, Rojo F, Perou C, Cortes J, Adamo V, Albanell J, Gomis R, Lluch A, Prat A

Publicada: 1 may 2017
Resumen:
Biological changes that occur during metastatic progression of breast cancer are still incompletely characterized. In this study, we compared intrinsic molecular subtypes and gene expression in 123 paired primary and metastatic tissues from breast cancer patients. Intrinsic subtype was identified using a PAM50 classifier and chi(2) tests determined the differences in variable distribution. The rate of subtype conversion was 0% in basal-like tumors, 23.1% in HER2-enriched (HER2-E) tumors, 30.0% in luminal B tumors, and 55.3% in luminal A tumors. In 40.2% of cases, luminal A tumors converted to luminal B tumors, whereas in 14.3% of cases luminal A and B tumors converted to HER2-E tumors. We identified 47 genes that were expressed differentially in metastatic versus primary disease. Metastatic tumors were enriched for proliferation-related and migration-related genes and diminished for luminal-related genes. Expression of proliferation-related genes were better at predicting overall survival in metastatic disease (OSmet) when analyzed in metastatic tissue rather than primary tissue. In contrast, a basal-like gene expression signature was better at predicting OSmet in primary disease compared with metastatic tissue. We observed correlations between time to tumor relapse and the magnitude of changes of proliferation, luminal B, or HER2-E signatures in metastatic versus primary disease. Although the intrinsic subtype was largely maintained during metastatic progression, luminal/HER2-negative tumors acquired a luminal B or HER2-E profile during metastatic progression, likely reflecting tumor evolution or acquisition of estrogen independence. Overall, our analysis revealed the value of stratifying gene expression by both cancer subtype and tissue type, providing clinicians more refined tools to evaluate prognosis and treatment. (C) 2017 AACR.

Filiaciones:
Cejalvo J:
 August Pi & Sunyer Biomed Res Inst IDIBAPS, Translat Genom & Targeted Therapeut Solid Tumors, Barcelona, Spain

 Inst Res Biomed IRB Barcelona, Oncol Program, Barcelona, Spain

De Duenas E:
 Hosp Prov Castellon, Castellon de La Plana, Spain

 Spanish Breast Canc Grp, GEICAM, Madrid, Spain

Galvan P:
 Vall dHebron Inst Oncol VHIO, Translat Genom Grp, Barcelona, Spain

Garcia-Recio S:
 August Pi & Sunyer Biomed Res Inst IDIBAPS, Translat Genom & Targeted Therapeut Solid Tumors, Barcelona, Spain

Gasion O:
 Spanish Breast Canc Grp, GEICAM, Madrid, Spain

 Hosp Clin Univ Valencia, Dept Pathol, Valencia, Spain

Pare L:
 August Pi & Sunyer Biomed Res Inst IDIBAPS, Translat Genom & Targeted Therapeut Solid Tumors, Barcelona, Spain

Antolin S:
 Spanish Breast Canc Grp, GEICAM, Madrid, Spain

 Complejo Hosp Univ A Coruna, La Coruna, Spain

Martinello R:
 August Pi & Sunyer Biomed Res Inst IDIBAPS, Translat Genom & Targeted Therapeut Solid Tumors, Barcelona, Spain

Blancas I:
 Spanish Breast Canc Grp, GEICAM, Madrid, Spain

 Complejo Hosp Granada, Hosp Clin San Cecilio, Granada, Spain

Adamo B:
 August Pi & Sunyer Biomed Res Inst IDIBAPS, Translat Genom & Targeted Therapeut Solid Tumors, Barcelona, Spain

Guerrero-Zotano A:
 Spanish Breast Canc Grp, GEICAM, Madrid, Spain

 Inst Valenciano Oncol, Valencia, Spain

Munoz M:
 August Pi & Sunyer Biomed Res Inst IDIBAPS, Translat Genom & Targeted Therapeut Solid Tumors, Barcelona, Spain

Nuciforow P:
 Vall dHebron Inst Oncol VHIO, Translat Genom Grp, Barcelona, Spain

Vidal M:
 August Pi & Sunyer Biomed Res Inst IDIBAPS, Translat Genom & Targeted Therapeut Solid Tumors, Barcelona, Spain

Perez R:
 Spanish Breast Canc Grp, GEICAM, Madrid, Spain

 Hosp Univ Quiron Madrid, Madrid, Spain

Lopez-Muniz J:
 Spanish Breast Canc Grp, GEICAM, Madrid, Spain

 Hosp Virgen de la Salud, Toledo, Spain

Caballero R:
 Spanish Breast Canc Grp, GEICAM, Madrid, Spain

Peg V:
 Hosp Valle De Hebron, Pathol Dept, Barcelona, Spain

Carrasco E:
 Spanish Breast Canc Grp, GEICAM, Madrid, Spain

Rojo F:
 Spanish Breast Canc Grp, GEICAM, Madrid, Spain

 Fdn Jimenez Diaz, Madrid, Spain

 CIBERONC ISCIII, Ctr Invest Biomed Red Oncol, Madrid, Spain

Perou C:
 Univ N Carolina, Chapel Hill, NC USA

Cortes J:
 Spanish Breast Canc Grp, GEICAM, Madrid, Spain

 Ramon & Cajal Univ Hosp, Madrid, Spain

Adamo V:
 Univ Messina, Messina, Italy

Albanell J:
 Spanish Breast Canc Grp, GEICAM, Madrid, Spain

 Hosp Mar, Barcelona, Spain

 CIBERONC ISCIII, Ctr Invest Biomed Red Oncol, Madrid, Spain

Gomis R:
 Inst Res Biomed IRB Barcelona, Oncol Program, Barcelona, Spain

 ICREA, Barcelona, Spain

Lluch A:
 Spanish Breast Canc Grp, GEICAM, Madrid, Spain

 Univ Valencia, Biomed Res Inst INCLIVA, Dept Hematol & Med Oncol, Valencia, Spain

 CIBERONC ISCIII, Ctr Invest Biomed Red Oncol, Madrid, Spain

Prat A:
 August Pi & Sunyer Biomed Res Inst IDIBAPS, Translat Genom & Targeted Therapeut Solid Tumors, Barcelona, Spain

 Vall dHebron Inst Oncol VHIO, Translat Genom Grp, Barcelona, Spain
ISSN: 00085472





Cancer Research
Editorial
AMER ASSOC CANCER RESEARCH, 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA, Estados Unidos America
Tipo de documento: Article
Volumen: 77 Número: 9
Páginas: 2213-2221
WOS Id: 000400270100006
ID de PubMed: 28249905

MÉTRICAS